about
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.PK evaluation of fondaparinux sodium for the treatment of thrombosis.Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty: A Randomized Controlled Trial.Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies.Population pharmacokinetic model of free and total ropivacaine after transversus abdominis plane nerve block in patients undergoing liver resection.Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite.Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.Quantification of total and unbound tranexamic acid in human plasma by ultrafiltration liquid chromatography/tandem mass spectrometry: application to pharmacokinetic analysis.Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!Investigation of drug-drug interactions between clopidogrel and fluoxetine.Antipsychotics: a real or confounding risk factor for venous thromboembolism?Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study.In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice.A new Strategy to Improve Drug Delivery to the Maxillary Sinuses: The Frequency Sweep Acoustic Airflow.Effect of Activated Charcoal on Rivaroxaban Complex Absorption.Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension.Prevalence of poor biological response to clopidogrel: a systematic review.Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.Interindividual variability in dabigatran and rivaroxaban exposure: contribution ofABCB1genetic polymorphisms and interaction with clarithromycinHPLC MS/MS method for quantification of meprobamate in human plasma: application to 24/7 clinical toxicology[Severe meprobamate poisoning: description of 146 cases in a French department]UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasmaUPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study[Direct oral anticoagulant, useful pharmacological characteristics in clinical practice]Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study[New oral anticoagulant pharmacology]Individualized PK-based prophylaxis in severe haemophiliaIncidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysisA new paradigm for personalized prophylaxis for patients with severe haemophilia ADirect oral anticoagulants: Still too early for prime time after pulmonary endarteriectomy?Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia APredicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approachRivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variabilityPharmacological characterization of the 3D MucilAir™ nasal model
P50
Q36988011-960C47C2-9170-40D5-BA21-4DDD94592256Q38173014-129E45F8-3CDB-4840-9426-414B904A6978Q38686421-E152DEE0-156C-4810-B8FF-2DFA9EE979F4Q38688723-9A4A1E17-5D1B-4BE0-959E-6B0EFAC3A29DQ38833665-FD3651C8-CA4B-4150-8C63-01639049F946Q38879025-056497F9-EA49-43E5-8656-2C9CDB409F22Q39492919-83B468EC-E3CE-4F5C-B327-0A80D5F318AAQ41368208-19F64C4E-D2AC-4B85-AA62-27799DE68CFEQ42942637-03CD6E9B-6F79-4205-9F1D-A9060D812024Q43038666-22E7EFF1-FB4D-494C-8370-9091A89BFADCQ43198338-D6C3E638-7718-4EAB-9277-2D45D2F5322FQ44329363-35057330-6B45-4DF2-BE53-DDB8BE1A6612Q44668895-447AD599-ECF8-41A9-8EC7-5D6BEC96F4D9Q45332852-6460A34F-7024-4387-8012-A6DBB570A0B4Q47356137-8E7C260D-82BE-480C-9B3B-17280167EF3BQ47386905-358E36C7-1004-4C0D-AFF6-95062890ADD6Q47819133-ABE579BD-DF36-4D48-A2B2-83372AD9BCA6Q50042940-FA5AE822-CD3A-4044-9E25-41E0163D167DQ50896805-B197D369-C5A8-442D-9F54-4B5E356299F5Q51032306-EE7B67CD-08C0-4079-95AE-C7AF744AFC0BQ51532142-6674CBC0-44E3-4304-89A5-43DE54FEA53DQ53094698-E0950AD8-3BE6-47AE-A00D-DA6B98FD31FCQ53129029-FC98EA30-1084-4355-A5FE-7D6EFE082BDBQ57314038-AF16D993-48F9-421A-86EC-F0288B7D9523Q83032160-7FF6607F-A309-4C3B-9CEA-CD2A169786B3Q84689727-5756CEB3-6290-41EF-9268-1694CAFD886CQ85089357-720259D8-8B61-4541-B447-407E86E23184Q85179226-3287C7AF-83DA-4E14-B36F-BEEEC502F348Q86385206-931AA465-8ABC-4C40-9CB0-755591A06FA6Q86409243-C3B199AE-9EE1-4E46-8701-C2A0373F183EQ87131843-A9003836-8214-46D8-AA0F-8CD1121862FDQ88066819-301A0D37-0D89-4F8A-B4B9-06CDF6AFA9ADQ89020351-E1625AF6-1B50-4409-85A7-04BBC7495959Q89890427-177EA867-F5A6-4CDF-BB22-37549F348F69Q89950765-5D28493C-4C7E-4BD4-967F-DB6834DF01DEQ91002708-2E1B46AE-BD82-40E9-8EF7-556A1B073C7BQ91620835-BA77B41B-BB4C-4157-A569-D020C1A64290Q92868498-C599E8BF-CA96-491B-8DCA-6CA1D2E0F557Q92879047-B6501876-47B7-4855-84D7-CD3EDD1EEFCC
P50
description
chercheur
@fr
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xavier Delavenne
@ast
Xavier Delavenne
@en
Xavier Delavenne
@es
Xavier Delavenne
@fr
Xavier Delavenne
@nl
Xavier Delavenne
@sl
type
label
Xavier Delavenne
@ast
Xavier Delavenne
@en
Xavier Delavenne
@es
Xavier Delavenne
@fr
Xavier Delavenne
@nl
Xavier Delavenne
@sl
prefLabel
Xavier Delavenne
@ast
Xavier Delavenne
@en
Xavier Delavenne
@es
Xavier Delavenne
@fr
Xavier Delavenne
@nl
Xavier Delavenne
@sl
P106
P21
P31
P496
0000-0001-7134-0713